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PAGE, sodium dodecyl sulfate polyacrylamide gel electBioluminescence energy transfer (BRET) is a powerful tool for the study of protein–protein interactions
and conformational changes within proteins. We directly compared two recently developed variants of
Renilla luciferase (RLuc), RLuc2 and RLuc8, as BRET donors using an in vitro thrombin assay. The compar-
ison was carried out by placing a thrombin-speciﬁc cleavage sequence between the donor luciferase and
a green ﬂuorescent protein (GFP2) acceptor. Substitution of native RLuc with the RLuc mutants, RLuc2 and
8, in a BRET2 fusion protein increased the light output by a factor of 10. Substitution of native RLuc with
either of the RLuc mutants resulted in a decrease in BRET2 ratio by a factor of 2 when BRET2 components
were separated by the thrombin cleavage sequence. BRET2 ratios changed by factors of 18.8 ± 1.2 and
18.2 ± 0.4 for GFP2-RG-RLuc2 and GFP2-RG-RLuc8 fusion proteins, respectively, on thrombin cleavage
compared to 28.8 ± 0.20 for GFP2-RG-RLuc. The detection limits for thrombin were 0.23 and 0.26 nM
for RLuc2 and RLuc8 BRET2 systems, respectively, and 15 pM for GFP2-RG-RLuc. However, overall, the
mutant BRET systems remain more sensitive than FRET and brighter than standard BRET2.
Crown Copyright  2012 Published by Elsevier Inc. Open access under CC BY-NC-ND license.Bioluminescence resonance energy transfer (BRET)1 is a natu-
rally occurring phenomenon found in a variety of marine organisms
such as Aequorea victoria and Renilla reniformis and results from the
nonradiative transfer of energy from a bioluminescent donor, Renilla
luciferase (RLuc) to a ﬂuorescent acceptor green ﬂuorescent protein
(GFP) [1]. Over the last decade, the BRET approach has been used
extensively for monitoring protein–protein interactions in living
cells, especially homo- and hetero-dimerization of G-protein coupled
receptors (GPCRs) [2]. It has also been used for monitoring GPCR
interactions with G-proteins [3] and b-arrestin [4,5] and interactions
between other proteins involved in GPCR function and regulation [6].
We recently demonstrated that BRET systems are more sensi-
tive than FRET for monitoring protease cleavage [7,8] and that
the optimal working distance of the BRET2 system is signiﬁcantly
larger than for FRET [9] making it more suitable for monitoring
conformational changes in GPCRs [10]. The BRET2 system uses
RLuc with the substrate coelenterazine 400a (Clz400a) as the en-
ergy donor and a green ﬂuorescent acceptor protein (GFP2) accep-
tor. Unfortunately, the advantages associated with the BRET2
system are partly outweighed by the low quantum yield and the
rapid decay kinetics of the Clz400a donor substrate. It was recentlyevier Inc.
.
ce energy transfer; GFP, green
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rophoresis.
Open access under CC BY-NCshown that the sensitivity of the BRET2 assay can be signiﬁcantly
improved by substituting native RLuc with mutant RLuc donors
with improved quantum yield and stability [11,12]. Substituting
RLuc8 for native RLuc in a BRET2 fusion protein increased the BRET
ratio by a factor of 5.5, thereby potentially enhancing the dynamic
range of the BRET2 system [12]. Improvements in the sensitivity of
BRET assays for the detection of ligand-induced GPCR–b-arrestin
interactions in live cells were also demonstrated [4,5]. Due to these
properties, RLuc variants, particularly RLuc8, are increasingly the
preferred luciferase donors for BRET-based reporter systems
[5,12–16]. It is now generally accepted that substitution of native
RLuc with RLuc2 or RLuc8 as the luciferase donor will improve
the performance characteristics of the BRET2 assay but this has
never been directly assessed in vitro. Therefore we used a well-
established in vitro approach to test this assumption.
A thrombin-speciﬁc cleavage sequence was inserted between
the donor and the acceptor proteins allowing thrombin cleavage
to be detected through changes in the BRET2 signal. Thrombin is in-
volved in the regulation of blood coagulation [17], selectively
cleaving the Arg–Gly bonds of ﬁbrinogen to form ﬁbrin. The RLuc8
donor has been used as a BRET donor when coupled to quantum
dot acceptors for the detection of matrix metalloproteinase
(MMP) protease activity [13,16] but RLuc2 performance has not
been assessed using any protease-based biosensor. The results of
this study demonstrate that the increase in luminescence afforded
to the BRET2 system by substituting RLuc with RLuc mutants
comes at the expense of assay sensitivity.-ND license.
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Materials
All primers (Table S1, Supplementary Material) were purchased
from Geneworks (Australia). RLuc2 and RLuc8 cDNAs were ampli-
ﬁed from constructs pcDNA3.1-RLucC124A/M185V (RLuc2) and
pcDNA3-RLuc8 and kindly provided by Sanjiv Gambhir (Stanford
University, CA, USA).
Construction of BRET proteins
RLuc2 and RLuc8 were ampliﬁed by polymerase chain reaction
(PCR) using the primers shown in Table S1 (Supplementary Mate-
rial) and cloned into pGEM-T Easy vector (Promega, Australia). This
resulted in the insertion of PstI and the sequence encoding the
thrombin recognition site (LQGSLVPRGSLQ) (A1)) or the caspase-
3 cleavage site (LQGSDEVDGSLQ (A2)) downstream of the ampli-
ﬁed gene and a XhoI restriction site (A3) directly upstream from
the ampliﬁed gene. The amplicons were inserted into the PstI
and XhoI sites of the pRSET GFP2-PstI-RLuc [8], replacing native
RLuc to give pRSET GFP2-RG-RLuc2, pRSET GFP2-DG-RLuc2, pRSET
GFP2-RG-RLuc8, and pRSET GFP2-DG-RLuc8 where RG represents
the linker sequence LQGSLVPRGSLQ and DG represents the linker
sequence LQGSDEVDGSLQ. All constructs were conﬁrmed by
sequencing. The construction of GFP2-RG-RLuc was described pre-
viously [8]. All fusion proteins contain a 6 His-tag located at the
N-terminus.
Expression and puriﬁcation of BRET-based proteins
Proteins were expressed in Escherichia coli strain BL21 (DE3)
(Novagen). An overnight culture was grown from a single colony
in LB (10 g tryptone, 5 g yeast extract, 5 g NaCl (pH 7.4)) containing
100 lg/mL ampicillin and 2% glucose at 37 C, 200 rpm. Expression
was induced by inoculating 500 mL LB containing 100 lg/mL
ampicillin to an A600 of 0.1 and incubating at 37 C (200 rpm) for
3.5 h followed by overnight incubation at 22 C (200 rpm). Cells
were harvested 24 h after inoculation.
For protein puriﬁcation, cells were harvested by centrifugation
at 4335g (4 C) for 15 min and resuspended in equilibration buffer
(57.7 mM Na2HPO4, 42.3 mM NaH2PO4, 300 mM NaCl, pH 7.0). The
cells suspension was passed through a homogenizer (Avestin
emulsiﬂex C3 (ATA Scientiﬁc, Australia)) at a pressure of 22,000
psi and the soluble protein fractions were isolated by centrifuga-
tion at 15,000g (4 C) for 15 min. Proteins were puriﬁed using
cobalt afﬁnity chromatography according to the supplied instruc-
tions (BD Talon (BD Biosciences, Clontech, Australia)). Following
elution of the puriﬁed protein with 150 mM imidazole, the sample
was dialyzed against thrombin cleavage buffer (50 mM Tris (pH 8),
100 mM NaCl, and 1 mM EDTA) [18] or caspase-3 cleavage buffer
(20 mM Pipes (pH 7.2), 100 mM NaCl, 1 mM Na-EDTA, 10 mM
DTT, 0.1% (w/v) Chaps, 10% (w/v) Sucrose) [19] using a cellulose
membrane (12,000 molecular weight cutoff (Sigma)). Aliquots of
500 lL protein were snap-frozen on dry ice and stored at 80 C.
Protein concentrations were determined by absorbance at
280 nm and calculated according to the method of Gill and von
Hippel [20].
Instrumentation
Spectral scans
All spectral scans were recorded with a SpectraMax M2
plate-reading spectroﬂuorimeter (Molecular Devices, Australia).
The reactions were carried out in 96-well plates (Perkin-Elmer,Australia). Bioluminescence scans of BRET2 constructs were re-
corded using the luminescence scan mode scanning between 360
and 650 nm.
Simultaneous dual emission detection
Simultaneous dual emission BRET measurements were carried
out with a POLARstar OPTIMA microplate reader (BMG LabTech,
Australia) using the BRET2 emission ﬁlter set comprising RLuc/
Clz400a emission ﬁlter (410 nm bandpass 80 nm) and the GFP2
emission ﬁlter (515 nm bandpass 30 nm).
Thrombin assays
Thrombin assays were carried out in 96-well plates by incubat-
ing puriﬁed fusion protein (1 lM) with varying amounts of throm-
bin protease (Quantum Scientiﬁc, Australia) in cleavage buffer
(ﬁnal volume of 100 lL) at 30 C for 90 min and then recording
the BRET2 signal. For BRET2 measurements 5 lM Clz400a substrate
(Biosynth AG, Switzerland) was added following the 90-min period
and a 0.50-s integration time was used.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–
PAGE) analysis
Proteins (2.5 lg) were diluted in 1X sample loading buffer
(Invitrogen, Australia) for SDS-gel electrophoresis (NuPAGE sys-
tem: 12% Bis-Tris gel with Mops running buffer (Invitrogen, Aus-
tralia)). After electrophoresis, the gels were washed three times
in 60 ml of 45% (v/v) methanol, 10% (v/v) acetic acid for 10 min
at room temperature with gentle agitation. Following the third
wash, the gel was submerged in 16% (v/v) Fast Stain (Fisher Scien-
tiﬁc, Australia) overnight with gentle shaking. Gels were destained
by washing three times in 10% (v/v) acetic acid solution for 10 min
with gentle shaking. Gels were photographed with transmitted
ﬂuorescent illumination using an AlphaImager 2200 video capture
imaging system (Alpha Innotech Corporation).
Hirudin Inhibition of thrombin protease
Recombinant hirudin from yeast (Sigma, Australia) was incu-
bated with equal units of thrombin at room temperature for
10 min prior to implementation of thrombin assays.
Analysis
BRET2 ratios are the ratio of integrated GFP2 channel intensity
(515 nm bandpass, 30 nm) divided by the integrated RLuc/Clz400a
channel intensity (410 nm bandpass, 80 nm) [7,8]. All data are re-
ported as means ± standard deviations (SD) (n = 3) of replicate
measurements made on different days on three independently pro-
duced batches of protein, unless otherwise stated. Normalized
BRET2 ratios were calculated by dividing calculated BRET2 ratios
following thrombin cleavage by the calculated BRET2 ratios with-
out the addition of thrombin. Two-tailed unpaired t tests were per-
formed using Graphpad prism (version 5.00 for Windows,
Graphpad Software, San Diego, CA, USA). Statistical signiﬁcance
was deﬁned as P < 0.05. Bioluminescence half-lives were estimated
by nonlinear regression analysis ﬁtting the data to a one-phase
exponential decay using GraphPad Prism for Windows Version
5.00.
Detection limits were calculated using [21]:
Limit of detection ðyÞ ¼ yb þ 3Sb; ð1Þ
where yb = a, the y-axis intercept of least squares regression line
and:
Fig.2. BRET2 ratio (mean ± SD, n = 3) of 1 lM of fusion proteins, GFP2-RG-RLuc2 and
GFP2-RG-RLuc8, on addition of 5 lM Clz400a substrate following treatment
(90 min, 30 C) with 54 nM thrombin and 54 nM thrombin following pretreatment
(10 min, room temperature) with 2 units of hirudin. Controls consist of 1 lM of a
mixture of both donor (RLuc2 or 8) and GFP2 acceptor.
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where
Sy=x ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
iðyi  byiÞ2
n 2
s
; ð3Þ
where yi = experimental y values, byi = ﬁtted values to calculated
least squares regression line, n = number of y values.
Limit of detection ðx valueÞ ¼ ð3 Sy=xÞ=b ð4Þ
where b = slope of ﬁtted least squares regression line.
Results and discussion
Luminescence intensity
Substitution of native RLuc with either RLuc mutant increased
the light output of the BRET2 fusion proteins by a factor of 10
(Fig. 1). The intensity of the integrated BRET2 signal was
(3.78 ± 0.11)  103 (n = 3) relative light units (RLU)/pmol protein
for GFP2-RG-RLuc, (39.13 ± 0.62)  103 RLU/pmol protein (n = 3)
for GFP2-RG-RLuc2 and (36.75 ± 1.02)  103 RLU/pmol protein
(n = 3) for GFP2-RG-RLuc8. This is a similar order of magnitude to
the observed increase in quantum yield for the Clz400a substrate
in the isolated RLuc2 and RLuc8 variants of native RLuc [11].
BRET2 ratio
The BRET2 ratio, integrated GFP2 channel intensity divided by
integrated RLuc/Clz400a channel intensity, of GFP2-RG-RLuc was
previously calculated to be 6.21 ± 0.18 [8] compared to
3.37 ± 0.02 for GFP2-RG-RLuc2 and 3.06 ± 0.24 for GFP2-RG-RLuc8
calculated here (Fig. 2). Substitution of native RLuc with either RLuc
mutant resulted in a decrease in BRET2 ratio by a factor of 2 when
BRET2 components were separated by the thrombin cleavage se-
quence. We had anticipated that substitution of native RLuc with
either RLuc mutant would increase the BRET2 ratio of the BRET2 fu-
sion proteins based on previous reports [12] of a 5.5-fold increase in
BRET2 ratio following substitution of RLuc8 for RLuc in GFP2-RG-
RLuc [8]. The BRET2 components in the GFP2-RLuc plasmid are sep-
arated by a multiple cloning site encoding a 16 amino acid linker
(SGSSLTGTRSDIGPSR) [12] compared to a 12 amino acid linker
(LQGSLVPRGSLQ) here. Our contrasting results may be due to the
different natures of these linker sequences and the effect this has
on relative orientations of dipoles of the BRET donor and acceptor.
To further investigate the effect of the linker sequence on BRET2
energy transfer, a caspase-3 cleavage sequence was insertedFig.1. Emission spectra of 1 lM of the speciﬁed GFP2-RG-RLuc, GFP2-RG-RLuc2, and
GFP2-RG-RLuc8 following addition of 16.7 lM Clz400a substrate (mean ± SD, n = 3).
Spectral scans of multiple wells (n = 3) for each protein sample were recorded using
the SpectraMax M2 spectroﬂuorimeter.between the BRET2 donor and the acceptor to give the following fu-
sion proteins: GFP2-DG-RLuc, GFP2-DG-RLuc2, and GFP2-DG-
RLuc8. Their measured BRET2 ratios were 3.77 ± 0.02 [7],
2.52 ± 0.34, and 2.39 ± 0.11, respectively. The order of the ampli-
tudes of their BRET2 ratios, RLuc > RLuc2 > RLuc8, was the same
as for the thrombin cleavage sequence. Also, all BRET2 fusion pro-
teins incorporating the caspase-3 target sequence produced lower
BRET2 ratios than the corresponding fusion proteins separated by
the thrombin cleavage target sequence. We have previously attrib-
uted this to the effect of using different buffer systems to optimize
cleavage conditions for each individual protease [7].
It was previously reported that replacement of native RLuc with
M185V RLuc mutants improved the quantum yield, leading to
BRET ratios increasing by factors of 3.4 for RLuc2 and 5.5 for RLuc8
[12]. In this study there was a decrease in BRET2 ratio when RLuc
mutants were substituted for native RLuc in the BRET2 fusion pro-
teins. This discrepancy may partly arise due to the different expres-
sion system, BRET constructs, and measurement techniques used
by De et al. [12] in comparison to those used in the present study.
The rate of RLuc inactivation observed in mammalian cells was an
order of magnitude slower than that observed in serum [12]. In our
thrombin cleavage buffer, the calculated half-life of the biolumi-
nescence decay of GFP2-RG-RLuc was determined to be 28.9 s com-
pared to 22.7 s for GFP2-RG-RLuc2 and 19.8 s for GFP2-RG-RLuc8
(Fig. 3). This is the same relative order (RLuc > RLuc2 > RLuc8) as
for the BRET2 ratio intensities (Fig. 2) and the light intensities
(Fig. 1).
Thrombin cleavage
BRET2 assays
GFP2-RG-RLuc2 and GFP2-RG-RLuc8 fusions were cleaved with
54 nM thrombin for 90 min, which changed the BRET2 ratios by
factors of 18.8 ± 1.2 and 18.2 ± 0.4, respectively (Fig. 2). The ﬁnal
Fig.3. Decay of bioluminescence (RLU) measured using the RLuc/Clz400a emission
ﬁlter (410 nm bandpass 80 nm) and an integration time of 0.5 s; bioluminescence
intensity is normalized by intensity at time = 0 (mean ± SD, n = 3).
Fig.4. Calibration of thrombin concentration with 1 lM GFP2-RG-RLuc2 and GFP2-
RG-RLuc8 on addition of 5 lM Clz400a substrate (mean ± SD, n = 3).
Fig.5. Linear calibration of thrombin concentration with 1 lM GFP2-RG-RLuc2 and
GFP2-RG-RLuc8 on addition of 5 lM Clz400a substrate (mean ± SD, n = 3).
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obtained by mixing 1 lM each of either donor with acceptor (con-
trol response), conﬁrming that full cleavage had occurred (Fig. 2).
Under identical assay conditions the change in BRET2 ratios is
approximately the same with either of the two RLuc variants.
The corresponding thrombin-catalyzed change in the BRET2 ra-
tios of the GFP2-RG-RLuc fusion was 28.8 ± 0.20. Therefore, under
identical assay conditions the change in recorded BRET2 ratios
was approximately 1.5-fold higher for the original BRET2 system
compared with systems incorporating RLuc2 or RLuc8.
Speciﬁcity
Preincubation of thrombin with two units of hirudin, which is
known to stably inhibit thrombin [18], abolished any changes in
BRET2 ratio for either RLuc2 or RLuc8 BRET2 systems, indicating
that the change in BRET2 ratio on addition of thrombin is abso-
lutely thrombin dependent (Fig. 2).
We mixed thrombin with each puriﬁed fusion protein to char-
acterize the cleavage products (Fig. S1, Supplementary Material).
Incubation with thrombin followed by SDS–PAGE conﬁrmed the
conversion of a single 68.8-kDa band, the fusion protein, into com-
ponents of 32.4 and 36.4 kDa, corresponding to His-tagged GFP2
and untagged RLuc2 (Fig. 4A) or RLuc8 (Fig. 4B). Preincubation with
hirudin completely inhibited this conversion, conﬁrming the spec-
iﬁcity of the cleavage.
Thrombin quantiﬁcation
The sensitivities of the two BRET2 assays were compared by
incubating 1 lM of either the GFP2-RG-RLuc2 or GFP2-RG-RLuc8
fusion with increasing concentrations of thrombin (Fig. 4). This is
the ﬁrst report of the use of these RLuc variants in a BRET2-based
in vitro assay for the quantitative determination of thrombin. The
BRET2 ratio changed linearly with increasing concentrations of
thrombin up to 2.7 nM for both BRET2 fusion proteins (Fig. 4). Cal-
ibrations were linear in these regions with R2 values exceeding
0.99 (Fig. 5).
Comparison of the gradients of the calibrations (Fig. 5) revealed
that the sensor incorporating the RLuc2 donor (y = 5.25x + 1.37) is
marginally more sensitive, 1.2-fold, to changing thrombin concen-
trations than the one with RLuc8 (y = 4.49x + 1.33). The calculated
detection limits (see Materials and methods (Eqs. (1)–(4)) for for-
mulas and explanation) for thrombin were 0.23 and 0.26 nM for
RLuc2 and RLuc8 BRET2 systems, respectively. Both BRET2 systemsdescribed here are an order of magnitude less sensitive for throm-
bin detection than the native RLuc BRET2 system, which had a
detection limit of 0.015 nM and a dynamic range extending up to
5.4 nM [7] but an order of magnitude more sensitive than the FRET
system [8] (Table S2, Supplementary Material). The detection limit
for BRET detection of MMP-7 cleavage of RLuc8-QD655 linked by a
MMP speciﬁc substrate was 0.26 nM [13], a similar sensitivity to
the mutant BRET2 systems characterized here.
Although BRET2 systems incorporating RLuc2 and 8 have lower
sensitivities and higher detection limits for thrombin than the na-
tive RLuc BRET2 system they are both sufﬁciently sensitive for
measuring thrombin concentrations associated with plasma clots,
estimated to be 0.46 nM [22].
Identifying acceptor molecules with large Stokes shifts that
maintain a good spectral overlap with the RLuc donor emission
spectrum may offer the greatest improvement to the sensitivity
of BRET2-based assays. For instance, a novel BRET system (BRET3),
combining a mutant red ﬂuorescent protein (mOrange) with RLuc8
and the BRET2 substrate donor exhibited several-fold improvement
over existing BRET fusion proteins, including GFP2-RLuc8 [23]. An
alternative approach would be to use novel Clz400a derivatives,
which have been shown to improve the signal to noise ratio and
the emission lifetime of the GFP-RLuc8 BRET2 system while main-
taining good spectral resolution between donor and acceptor emis-
sion peaks [24].
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We conclude that the increase in luminescence afforded to the
BRET2 system by substitution of native RLuc by RLuc2 or RLuc8 in
practice comes at the expense of assay sensitivity. However, over-
all these mutant systems are still more sensitive than FRET and
brighter than standard BRET2. The increase in luminescence with
the modiﬁed BRET2 systems could lead to shorter acquisition times
and allows the use of lower amounts of protein and lower sub-
strate concentrations, which would have considerable practical
advantages. This study highlights the fact that it is inadvisable to
draw conclusions based solely on the performance of individual
BRET components without testing how the system as a whole
performs.
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